How do orthopedic oncology clinic nurses explain to a Spanish-speaking family with a teenager diagnosed with Ewing sarcoma why chemotherapy must begin before surgery, and what happens if the family insists on operating immediately?

The family of a patient with Ewing sarcoma who insists on immediate surgery has arrived at a conclusion that feels exactly right from outside medicine: the tumor is visible on the imaging, it is in the bone, surgery removes things that are in places they should not be, and every day that the tumor remains is a day it could spread. This reasoning is not wrong — it is just incomplete in a way that changes the answer entirely. Ewing sarcoma is not a disease that has a primary tumor and then, later, might spread. At the time of diagnosis, approximately 25 percent of patients have visible metastases on staging imaging, but the meaningful number is much higher: nearly all patients with high-grade Ewing sarcoma have microscopic hematogenous dissemination at diagnosis, meaning that tumor cells have already entered the bloodstream and are circulating to lungs, bone marrow, and other sites in quantities too small for any current imaging to detect. Surgery on the primary tumor does not address those cells. A surgeon who removes the distal femur tumor on day one has done nothing about the cells that are already in the pulmonary vasculature. The patient would recover from surgery, and within months metastatic disease would appear in the lungs — which it would have done more slowly if neoadjuvant chemotherapy had been initiated immediately. The purpose of neoadjuvant chemotherapy — six cycles of VIDE or VDC/IE given over approximately twelve weeks before surgery — is to begin treating the whole body immediately, including the micrometastatic deposits the imaging cannot show. At the same time, neoadjuvant chemotherapy reduces the volume of the primary tumor: a femoral Ewing sarcoma that occupies 12 cm of cortical bone and involves the surrounding soft tissue at diagnosis may shrink by 40 to 60 percent in diameter over twelve weeks of chemotherapy, and this size reduction determines whether the surgeon can achieve clear margins while preserving the limb. A tumor of 12 cm in a 17-year-old's femur operated on day one may require amputation or hemipelvectomy to achieve clear margins. The same tumor after twelve weeks of chemotherapy may be resectable with a limb-sparing wide excision and endoprosthetic reconstruction — preserving the leg. But the most important reason for neoadjuvant chemotherapy is not surgery planning: it is that the histological response to neoadjuvant chemotherapy is the strongest prognostic factor in Ewing sarcoma. When the surgeon removes the tumor after twelve weeks of chemotherapy, the pathologist analyzes the resected specimen under the microscope and counts what percentage of the tumor cells are dead. Greater than 90 percent necrosis — dead tumor cells — is a 'good histological response.' Less than 90 percent is a 'poor histological response.' Patients who achieve a good histological response have a five-year event-free survival of approximately 70 to 80 percent. Patients with a poor response have a five-year event-free survival of approximately 40 to 50 percent. This number cannot be obtained without giving neoadjuvant chemotherapy and waiting to see how the tumor responds. The family who insists on immediate surgery forfeits this information. In Spanish: 'Entiendo perfectamente por qué quieren operar ya. El tumor está ahí y quieren quitarlo. Eso tiene todo el sentido del mundo. Lo que quiero explicarles es que el sarcoma de Ewing es una enfermedad del cuerpo entero desde el día del diagnóstico, no solo un tumor en el fémur. En el 25 por ciento de los pacientes, ya hay metástasis visibles en las imágenes en el momento del diagnóstico. En casi todos los demás, hay células del tumor que ya salieron al torrente sanguíneo — están en el cuerpo, pero son demasiado pequeñas para que cualquier imagen las detecte. Si operamos mañana y quitamos el tumor del fémur, no hacemos nada con esas células. La quimioterapia que vamos a empezar esta semana trata todo el cuerpo — incluyendo esas células microscópicas. Al mismo tiempo, la quimioterapia reduce el tamaño del tumor aquí en el fémur, y eso cambia lo que es posible en la cirugía: si el tumor reduce suficiente, podemos operar preservando la pierna. Sin la quimioterapia primero, probablemente necesitaríamos amputar para tener márgenes limpios. Hay otro motivo, igualmente importante: cuando el cirujano opere después de la quimioterapia, el patólogo va a analizar cuántas células del tumor murieron con la quimio. Si más del 90 por ciento están muertas, es una respuesta excelente y eso nos dice que el tratamiento está funcionando. Esa información guía toda la quimioterapia después de la cirugía. Esa información solo existe si empezamos la quimio primero.' (I understand perfectly why you want to operate now. The tumor is there and you want it removed. That makes complete sense. What I want to explain is that Ewing sarcoma is a disease of the whole body from the day of diagnosis, not just a tumor in the femur. In 25 percent of patients, there are already visible metastases on imaging at the time of diagnosis. In nearly all the others, there are tumor cells that have already entered the bloodstream — they are in the body, but they are too small for any imaging to detect. If we operate tomorrow and remove the tumor from the femur, we do nothing about those cells. The chemotherapy we are going to begin this week treats the whole body — including those microscopic cells. At the same time, chemotherapy reduces the size of the tumor here in the femur, and that changes what is possible in surgery: if the tumor shrinks enough, we can operate preserving the leg. Without chemotherapy first, we would probably need to amputate to achieve clean margins. There is another equally important reason: when the surgeon operates after chemotherapy, the pathologist will analyze how many tumor cells died with chemotherapy. If more than 90 percent are dead, that is an excellent response and tells us the treatment is working. That information guides all the chemotherapy after surgery. That information only exists if we start chemotherapy first.)

How do orthopedic oncology clinic nurses explain to a Spanish-speaking patient with a giant cell tumor of bone why the tumor was treated with curettage and denosumab rather than removed entirely, when the family believes the safest approach is complete removal?

The patient with a giant cell tumor of bone who asks why the tumor was not simply removed has made the same inference that most patients make when they hear the word 'tumor': that removal is the safest option and that leaving any portion of the tumor in the body is a concession. This inference applies to many solid tumors and is not unreasonable as a general principle — but giant cell tumor of bone is biologically and anatomically different in ways that invert the usual risk calculus. Giant cell tumor of bone is a WHO grade 2 to 3 locally aggressive tumor that is histologically benign — meaning it does not metastasize in the conventional sense and does not spread through the lymphatic system. The biologically relevant danger of giant cell tumor is local recurrence: tumor cells left behind after treatment re-populate the lesion. The question of curettage versus wide resection is not 'which option has a lower chance of recurrence' — wide resection has essentially zero local recurrence. The question is 'which option results in acceptable function at the price of acceptable recurrence risk.' For the distal radius — where Carmen's tumor is located — wide resection means removing the distal radius entirely. The distal radius is the bone that forms the wrist joint on the thumb side. Removing it requires reconstruction with either a fibular strut graft (harvesting a segment of the patient's own fibula) or a wrist arthrodesis (fusing the wrist in a fixed position). Both reconstructions produce significant permanent functional loss: the fibular graft reconstruction produces a wrist that moves in a limited arc and has reduced grip strength; wrist fusion eliminates flexion and extension entirely. A bilingual teacher who uses her hands for writing, typing, and classroom management will have her professional function significantly impaired by either reconstruction. Extended curettage — removing the tumor from the inside of the bone using curettes and a high-speed burr — followed by adjuvant treatment of the cavity walls (using phenol, hydrogen peroxide, or argon beam coagulation to kill residual cells in the bone surface) and filling with bone cement or graft achieves local control in 75 to 85 percent of patients. The 15 to 25 percent who recur can be re-curetted in most cases; the recurrence is detectable on imaging and is not metastasis. Denosumab changes this equation further. Giant cell tumors contain RANK-L–expressing stromal cells that drive osteoclastic destruction of the surrounding bone — that is why the tumor forms a lytic lesion. Denosumab is a fully human monoclonal antibody against RANK-L, the same mechanism used for osteoporosis, but at higher doses it halts osteoclast activation entirely in the tumor microenvironment. Over six to twelve months of denosumab treatment, the tumor undergoes ossification — the lytic cavity fills in with new bone — and the cortical walls reconstitute. This makes subsequent curettage more complete because the surgeon is operating on a better-defined, partially ossified lesion with intact cortex rather than an expanding lytic cavity in soft bone. It also converts some spine and sacral tumors that were unresectable without neurological sacrifice into tumors that can be curetted. For Carmen's distal radius GCTB, the sequence is denosumab to consolidate the lesion, then extended curettage with adjuvant and cementation, with wrist function preserved. In Spanish: 'Le quiero explicar exactamente por qué tomamos esta decisión, porque tiene todo el sentido del mundo preguntarlo. El tumor de células gigantes del hueso es diferente a lo que la mayoría de la gente imagina cuando escucha la palabra tumor. No se disemina por el sistema linfático — no hace metástasis de la misma manera que otros tumores. El riesgo principal es que si quedan células después del tratamiento, el tumor puede crecer de nuevo en el mismo lugar. Eso se detecta con imágenes de seguimiento y se puede tratar de nuevo. La cirugía que más garantiza cero recurrencia es la resección completa — quitar el radio distal entero. Pero el radio distal es el hueso que forma la muñeca del lado del pulgar. Si lo quitamos, necesitamos reconstruir la muñeca con un injerto del peroné o fusionar la muñeca en posición fija. Cualquiera de las dos opciones limita permanentemente el movimiento de la muñeca y la fuerza del agarre. Para una maestra que usa las manos para escribir y trabajar en el salón, eso es una pérdida funcional seria. El raspado extendido — que es sacar el tumor de adentro del hueso y tratar las paredes de la cavidad para matar cualquier célula que quede — seguido del denosumab que usted está tomando, da control local en el 75 al 85 por ciento de los casos, con la muñeca funcionando. El denosumab hace que el tumor se consolide antes de la cirugía definitiva — las paredes del hueso se recuperan, y eso hace que la cirugía sea más completa. El objetivo es preservar su muñeca mientras controlamos el tumor, y eso es lo que estamos haciendo.' (I want to explain exactly why we made this decision, because it makes complete sense to ask. Giant cell tumor of bone is different from what most people imagine when they hear the word tumor. It does not spread through the lymphatic system — it does not metastasize in the same way as other tumors. The main risk is that if cells remain after treatment, the tumor can grow back in the same place. That is detected on follow-up imaging and can be treated again. The surgery that most guarantees zero recurrence is complete resection — removing the entire distal radius. But the distal radius is the bone that forms the wrist on the thumb side. If we remove it, we need to reconstruct the wrist with a graft from the fibula or fuse the wrist in a fixed position. Either option permanently limits wrist movement and grip strength. For a teacher who uses her hands for writing and classroom work, that is a serious functional loss. Extended curettage — removing the tumor from inside the bone and treating the cavity walls to kill any remaining cells — followed by the denosumab you are taking, achieves local control in 75 to 85 percent of cases, with the wrist functioning. Denosumab consolidates the tumor before definitive surgery — the bone walls recover, and that makes the surgery more complete. The goal is to preserve your wrist while controlling the tumor, and that is what we are doing.)

How do orthopedic oncology clinic nurses explain to a Spanish-speaking family with a teenager diagnosed with osteosarcoma that delaying treatment by six to eight weeks for an international second opinion changes the histological response that determines long-term survival, and that a concurrent second opinion is achievable without treatment delay?

The family of a patient with osteosarcoma who wants a second opinion before starting treatment has made a reasonable decision: the diagnosis is serious, the treatment is aggressive, and the family has every right to be certain that the diagnosis and treatment plan are correct before proceeding. The question is not whether to seek a second opinion — a second opinion is appropriate and the care team should support it. The question is whether the second opinion requires delaying treatment, and the answer to that is no. The five-year overall survival for localized osteosarcoma treated with the MAP protocol — methotrexate, doxorubicin, and cisplatin given in three neoadjuvant cycles before surgery and three to five adjuvant cycles after — is approximately 65 to 70 percent. For metastatic osteosarcoma, it is approximately 20 to 30 percent. This is not a disease where a six-to-eight-week delay in initiating treatment is clinically trivial. The strongest prognostic variable in osteosarcoma — as in Ewing sarcoma — is the histological response to neoadjuvant chemotherapy: the percentage of tumor necrosis in the resected specimen after neoadjuvant chemotherapy. Greater than 90 percent necrosis is a good histological response. Less than 90 percent is a poor response, which triggers protocol intensification or enrollment in clinical trials. This number is determined by how the tumor responds to the first cycles of chemotherapy. Chemotherapy kills tumor cells that are dividing actively. Osteosarcoma at diagnosis is a highly proliferative tumor with rapid cellular division. During the six to eight weeks that a family waits for an international consultation, the tumor continues to divide and to establish new vascular ingrowth, which increases the fraction of cells in hypoxic microenvironments. Hypoxic tumor cells are intrinsically chemoresistant — they are dividing more slowly and have activated hypoxia-inducible pathways that upregulate drug efflux pumps. A tumor that has six to eight more weeks of vascular ingrowth and hypoxic adaptation is a tumor that is less likely to achieve greater than 90 percent necrosis in response to the first MAP chemotherapy cycles. The practical implication is that the delay does not just defer the start of treatment — it changes the tumor biology in a way that is measurable at the time of surgery and that correlates with long-term survival. The concurrent second opinion is real and achievable: all imaging — MRI, CT of chest and abdomen, nuclear bone scan, PET-CT if obtained — can be exported from the PACS system as DICOM files and sent electronically to any institution in Mexico City, the United States, or elsewhere within 24 hours. The biopsy blocks — the physical paraffin-embedded tissue samples — can be shipped to any pathology department in the world and reviewed by an independent pathologist in one to two weeks. A telemedicine consult with the family and a second-opinion sarcoma team in Mexico City can be arranged in parallel with the start of neoadjuvant chemotherapy here. If the family decides after the second opinion that they want to transfer care to Mexico City, the MAP protocol can be continued there without interruption — it is the same international standard used at every sarcoma center in Mexico, Spain, and Latin America. In Spanish: 'Buscar una segunda opinión es lo correcto. Les apoyamos completamente en eso, y se lo recomendamos. Lo que quiero explicarles es que la segunda opinión no tiene que retrasar el inicio del tratamiento, y que empezar el tratamiento aquí esta semana no cierra la puerta a que sigan con el tratamiento en México. El osteosarcoma responde muy bien a la quimioterapia cuando se empieza pronto. El dato más importante de todo el tratamiento es cuánto porciento del tumor murió con la quimioterapia cuando el cirujano opere — si más del 90 porciento está muerto, eso es una respuesta excelente y predice los mejores resultados a largo plazo. Ese porcentaje depende de cómo estaba el tumor cuando empezó la quimioterapia. Cada semana que el tumor sigue creciendo sin tratamiento, más células están en áreas con poco oxígeno dentro del tumor, y esas células son más difíciles de matar con quimioterapia. Podemos enviar todas las imágenes — la resonancia, el CT, el PET — a cualquier hospital en México por correo electrónico en 24 horas. Los bloques de la biopsia se pueden enviar físicamente al patólogo del hospital en México en una semana. Pueden tener una consulta de telemedicina con el equipo en México mientras Diego empieza la quimioterapia aquí. Y si después de esa consulta deciden continuar el tratamiento allá, el protocolo que vamos a usar aquí es el mismo que usan en los centros de sarcoma en México — Diego puede empezar aquí y continuar allá sin interrupción. Lo único que no podemos recuperar es el tiempo que el tumor sigue creciendo sin tratamiento.' (Seeking a second opinion is the right thing to do. We fully support you in that, and we recommend it. What I want to explain is that the second opinion does not have to delay the start of treatment, and that starting treatment here this week does not close the door to continuing treatment in Mexico. Osteosarcoma responds very well to chemotherapy when it is started soon. The most important data point in the entire treatment is what percentage of the tumor was killed by chemotherapy when the surgeon operates — if more than 90 percent is dead, that is an excellent response and predicts the best long-term outcomes. That percentage depends on how the tumor was when chemotherapy began. Every week that the tumor continues growing without treatment, more cells are in low-oxygen areas inside the tumor, and those cells are harder to kill with chemotherapy. We can send all the images — the MRI, CT, PET — to any hospital in Mexico by email within 24 hours. The biopsy blocks can be shipped physically to the pathologist at the hospital in Mexico within a week. You can have a telemedicine consultation with the team in Mexico while Diego starts chemotherapy here. And if after that consultation you decide to continue treatment there, the protocol we are going to use here is the same one used at sarcoma centers in Mexico — Diego can start here and continue there without interruption. The only thing we cannot recover is the time the tumor continues growing without treatment.)

What are the key Spanish phrases orthopedic oncology clinic nurses need for explaining neoadjuvant chemotherapy sequencing and bone tumor treatment decisions to Spanish-speaking patients and families?

Orthopedic oncology clinic nurses working with Spanish-speaking patients encounter three recurring explanation challenges: the neoadjuvant-before-surgery sequence, curettage-vs-resection for benign aggressive tumors, and how to support informed decision-making when families want to pursue care in another country. Core phrases for each: For neoadjuvant chemotherapy sequencing — 'La quimioterapia va primero porque el cáncer ya está en el cuerpo entero, aunque las imágenes solo muestren un lugar' (Chemotherapy comes first because the cancer is already in the whole body, even though the images only show one place); 'Quitar el tumor del hueso no trata las células que ya están en el torrente sanguíneo' (Removing the tumor from the bone does not treat the cells already in the bloodstream); 'La respuesta del tumor a la quimioterapia — cuánto porciento murió — es el dato más importante de todo el tratamiento' (The tumor's response to chemotherapy — what percentage died — is the most important data point in the entire treatment). For giant cell tumor curettage vs. resection — 'Este tumor no se disemina como otros tumores. El riesgo es que crezca de nuevo en el mismo lugar' (This tumor does not spread like other tumors. The risk is that it grows back in the same place); 'La cirugía completa curaría el tumor pero destruiría la función de la muñeca permanentemente' (Complete surgery would cure the tumor but would permanently destroy wrist function); 'El denosumab hace que el hueso se recupere antes de la cirugía, para que la cirugía sea más completa' (Denosumab causes the bone to recover before surgery, so the surgery can be more complete). For second-opinion treatment delay in osteosarcoma — 'La segunda opinión la apoyamos completamente. No tiene que retrasar el inicio del tratamiento' (We fully support the second opinion. It does not have to delay starting treatment); 'Podemos enviar todas las imágenes y la biopsia a México en días, mientras empieza la quimioterapia aquí' (We can send all the images and biopsy to Mexico within days, while chemotherapy starts here); 'El protocolo que usamos aquí es el mismo que usan en los centros de sarcoma en México — el tratamiento puede continuar sin interrupción si deciden transferir el cuidado' (The protocol we use here is the same used at sarcoma centers in Mexico — treatment can continue without interruption if you decide to transfer care).

How should orthopedic oncology clinic nurses approach the cultural dimension of bone tumor treatment conversations with Spanish-speaking families who prioritize family consensus and want to wait for input from relatives abroad before agreeing to treatment?

Orthopedic oncology clinic nurses regularly encounter families where treatment decisions are made by an extended network — grandparents, siblings, a respected uncle who is a physician in another country — rather than by the patient and immediate family alone. For a 14-year-old with osteosarcoma, the parents may not feel authorized to agree to a treatment plan without input from the patient's grandfather in Oaxaca, an aunt in Guadalajara who works as a nurse, or a family friend who is a surgeon in Monterrey. This is not obstruction: it is the patient's family trying to make the best decision they can within their actual social structure. The nurse's role is not to override this process but to make it compatible with the medical timeline. Several practical approaches reduce friction without dismissing the family structure. First, bring the extended network into the conversation directly: offer to conduct a video call with relatives abroad during the next appointment so that the grandmother or the surgeon uncle can hear the explanation firsthand and ask their own questions. A family member who hears the neoadjuvant rationale explained by the oncology team directly is more likely to support the plan than a family member who hears a second-hand account filtered through fear and translation. Second, frame the timeline explicitly: 'We need a decision about starting chemotherapy within the next four to five days. That is enough time to call your relatives, have a video visit here with them and our team, and make the decision together. It is not enough time to arrange travel to another country and begin treatment there.' Third, provide written materials in Spanish: a one-page summary of the MAP protocol, the histological response rationale, and the logistical steps for sharing records with an international center, gives the family something concrete to share with relatives abroad without relying on phone retelling. Fourth, explicitly validate that the family is doing the right thing by asking questions and seeking consensus: 'You are asking exactly the right questions. Most families who love someone they're about to put through chemotherapy ask these questions. The fact that you are asking means you understand what you're agreeing to.' In Spanish: 'Entiendo que quieren hablar con su familia antes de decidir. Eso tiene todo el sentido. Tenemos cuatro o cinco días antes de que necesitemos empezar. ¿Les ayudaría si organizamos una llamada de video con el médico de la familia en Monterrey para que pueda hacer sus propias preguntas al equipo directamente? También les puedo dar un resumen escrito en español de todo lo que hablamos hoy para que puedan compartirlo con sus familiares esta noche.' (I understand that you want to talk with your family before deciding. That makes complete sense. We have four or five days before we need to start. Would it help if we arranged a video call with the family doctor in Monterrey so he can ask his own questions directly to the team? I can also give you a written summary in Spanish of everything we discussed today so you can share it with your relatives tonight.)

Spanish for orthopedic oncology clinic nurses — the Ewing sarcoma patient who cannot understand why chemotherapy must begin before surgery and does not know the tumor has already spread beyond what imaging shows, the giant cell tumor patient who cannot understand why the surgeon treated the tumor from inside the bone rather than removing it and does not know curettage is the standard of care that preserves the joint, and the osteosarcoma family who wants to delay treatment for a second opinion in Mexico City and does not know every week of delay changes the histological response that determines long-term survival

The orthopedic oncology clinic’s communication challenge

Orthopedic oncology nurses work at the intersection of two domains that each generate their own patient misconceptions. From oncology, families bring the general principle that the goal of treatment is to eliminate the cancer, that treatment should begin immediately, and that any delay is dangerous. From surgery, families bring the general principle that if something is wrong with a body structure, the surgeon removes it. Both principles are usually correct. In bone tumor care, both can lead to the wrong conclusion.

The Ewing sarcoma family who wants surgery now is applying the surgery principle correctly to the wrong disease. Ewing sarcoma is not a disease that begins locally and then spreads; it has already spread, invisibly, in the majority of patients at diagnosis. Operating on the primary tumor without first treating the body systemically is analogous to mopping a floor that is still under a running faucet.

The giant cell tumor patient who questions whether curettage was adequate is applying the oncology principle correctly to the wrong biology. Giant cell tumor of bone is not a malignant tumor that spreads and kills. Its danger is local recurrence. The question is not “how do we eliminate all cancer cells” but “how do we achieve local control while preserving the joint that the patient uses every day to earn her living.”

The osteosarcoma family that wants to delay treatment is applying the second-opinion principle correctly to the wrong logistics. A second opinion is appropriate and supported. Delaying chemotherapy to obtain one is not — because the second opinion and the first treatment cycle can occur simultaneously, and because histological response to neoadjuvant chemotherapy is the strongest prognostic variable in the disease and is determined by what the tumor looks like when chemotherapy begins.

Each of these conversations requires the nurse to locate the exact point where the family’s model and the clinical reality diverge — and to explain that point clearly in Spanish, at the bedside, in a single conversation.

Scenario 1: Miguel Ángel Torres — 17, high school junior from San Antonio, Ewing sarcoma of the distal femur

Miguel Ángel Torres is seventeen years old, a junior at a high school in San Antonio where he plays varsity soccer. He presented with six weeks of worsening left knee pain and was referred to orthopedics after a femur radiograph showed a permeative lytic lesion involving the distal diaphysis with a Codman triangle and soft-tissue extension. MRI confirmed a 9.4 cm lesion with cortical breakthrough and a surrounding soft-tissue mass. CT of the chest and abdomen showed no visible pulmonary nodules. Bone marrow biopsy and PET-CT staging showed no distant lesions. Core needle biopsy confirmed Ewing sarcoma, EWSR1-FLI1 fusion transcript positive.

At the first orthopedic oncology clinic appointment, Miguel’s mother — Rosa Torres, a housekeeping supervisor who arrived with her husband and Miguel’s older sister — asked the first question before the nurse Isabel Reyes had finished the introduction: “Why isn’t he having surgery? They found the tumor. Why do they want to give him chemotherapy before they take it out?”

The father, José Torres, added: “He’s been having pain for six weeks. Every week that tumor is still there, it can be spreading. Doesn’t it make more sense to cut it out first and then do chemotherapy?”

Isabel had heard this question in exactly these words, or close to them, at least forty times in her five years as an orthopedic oncology nurse. She pulled her chair close to Rosa and began.

“Lo que dicen tiene todo el sentido del mundo desde afuera,” she said. (What you are saying makes complete sense from the outside.) “Ven un tumor. Un cirujano puede quitar cosas. ¿Por qué no quitarlo ya?” (You see a tumor. A surgeon can remove things. Why not remove it now?)

“Lo que quiero explicarles es que el sarcoma de Ewing es diferente a lo que la mayoría de la gente imagina cuando escucha la palabra tumor. No es un tumor que empieza aquí en el fémur y que algún día, si no lo tratan, se va a diseminar. En el momento en que lo diagnosticamos, el sarcoma de Ewing ya es una enfermedad del cuerpo entero.” (What I want to explain is that Ewing sarcoma is different from what most people imagine when they hear the word tumor. It is not a tumor that starts here in the femur and that someday, if untreated, will spread. At the moment we diagnose it, Ewing sarcoma is already a whole-body disease.)

She explained the numbers. In 25 percent of patients with Ewing sarcoma, metastases are already visible on staging imaging at diagnosis — in the lungs, in distant bones, in the lymph nodes. In the remaining 75 percent, imaging appears clear. But the reason Ewing sarcoma historically had a five-year survival rate below 10 percent before chemotherapy — when it was treated with surgery or radiation alone — is that nearly all of those patients who appeared to have localized disease developed metastases within one to two years of local treatment. Not because the tumor spread after treatment, but because it had already spread before treatment, in amounts too small for any imaging to detect.

“Si operamos a Miguel mañana y quitamos el tumor del fémur,” she said, “hacemos la cirugía perfectamente, márgenes limpios, ningún signo de tumor — y no hacemos nada con las células que ya salieron al torrente sanguíneo antes del diagnóstico. Esas células están en el cuerpo. Están en el pulmón, en la médula ósea, en lugares donde las imágenes de hoy no las pueden ver. En seis meses, van a aparecer metástasis en el pulmón, y en ese momento el sarcoma ya es enfermedad metastásica.” (If we operate on Miguel tomorrow and remove the tumor from the femur, we perform the surgery perfectly, clean margins, no sign of tumor — and we do nothing about the cells that have already entered the bloodstream before diagnosis. Those cells are in the body. They are in the lung, in the bone marrow, in places where today’s imaging cannot see them. In six months, metastases will appear in the lung, and at that point the sarcoma is already metastatic disease.)

Rosa stopped her: “¿Entonces ya tiene metástasis ahora?” (So he already has metastases now?)

“No tenemos evidencia de metástasis en ninguna imagen que hicimos,” Isabel answered. “Lo que les digo es que el comportamiento histórico del sarcoma de Ewing nos enseña que en la mayoría de los pacientes, las células ya salieron antes del diagnóstico aunque no haya metástasis visibles. Por eso usamos quimioterapia que trata todo el cuerpo desde el día uno.” (We have no evidence of metastases on any imaging we performed. What I am telling you is that the historical behavior of Ewing sarcoma teaches us that in the majority of patients, the cells have already left before diagnosis even though there are no visible metastases. That is why we use chemotherapy that treats the whole body from day one.)

She moved to the second reason: limb salvage. The tumor in Miguel’s distal femur was 9.4 cm with soft-tissue extension. Operated on today, the margins required to achieve an R0 resection would require removing the distal femur, the knee joint, and possibly a portion of the proximal tibia — and the reconstruction options in a 17-year-old include a growing endoprosthesis or a rotationplasty. After twelve weeks of VIDE chemotherapy, the same tumor was likely to shrink by 30 to 60 percent in its longest diameter. The soft-tissue mass would regress. The margins achievable with the same wide excision would be cleaner, and a limb-sparing resection with endoprosthetic reconstruction of the distal femur and knee would be feasible with a higher probability of the surgeon achieving R0 margins.

“La quimioterapia también reduce el tamaño del tumor aquí mismo,” she said, pointing to the MRI on the wall-mounted screen. “Este tumor mide nueve centímetros ahora, con tejido blando afuera del hueso. Si operamos ahora, para tener márgenes limpios probablemente necesitaríamos quitar la rodilla también. Si esperamos doce semanas de quimio, este tumor probablemente va a reducir a cuatro o cinco centímetros y el tejido blando se va a retraer. Eso cambia lo que el cirujano puede hacer: puede quitar el tumor con un margen limpio y reconstruir la rodilla con una prótesis, y Miguel puede conservar la pierna.” (Chemotherapy also reduces the size of the tumor right here. This tumor measures nine centimeters now, with soft tissue outside the bone. If we operate now, to achieve clean margins we would probably need to remove the knee as well. If we wait twelve weeks of chemotherapy, this tumor will likely shrink to four or five centimeters and the soft tissue will retract. That changes what the surgeon can do: he can remove the tumor with a clean margin and reconstruct the knee with a prosthesis, and Miguel can keep his leg.)

The father leaned forward: “¿Y qué pasa si la quimio no funciona? ¿No se está poniendo peor el tumor mientras esperamos?” (And what if the chemotherapy doesn’t work? Isn’t the tumor getting worse while we wait?)

Isabel had expected this. “Esa es exactamente la pregunta correcta, y tiene respuesta. Cuando el cirujano opere después de la quimioterapia, el patólogo va a analizar el tumor bajo el microscopio y contar cuántas células están muertas. Si más del noventa porciento están muertas, es una respuesta excelente. Si menos del noventa porciento están muertas, ajustamos la quimioterapia después de la cirugía. Ese número — cuánto porciento del tumor murió con la quimio — es el dato más importante de todo el tratamiento. Es el predictor más fuerte de qué va a pasar a largo plazo. Ese número solo existe si empezamos la quimio primero.” (That is exactly the right question, and it has an answer. When the surgeon operates after chemotherapy, the pathologist will analyze the tumor under the microscope and count how many cells are dead. If more than 90 percent are dead, that is an excellent response. If fewer than 90 percent are dead, we adjust chemotherapy after surgery. That number — what percentage of the tumor was killed by chemotherapy — is the most important data point in the entire treatment. It is the strongest predictor of what will happen long-term. That number only exists if we start chemotherapy first.)

Rosa and José looked at each other. Rosa asked one more question: “¿Cuánto tiempo va a tomar la quimio antes de la cirugía?” (How long will chemotherapy take before surgery?)

“Doce semanas — seis ciclos. Después viene la cirugía. Después más quimio. El tratamiento completo es aproximadamente diez meses.” (Twelve weeks — six cycles. Then surgery. Then more chemotherapy. The complete treatment is approximately ten months.)

Miguel, who had been quiet through the conversation, spoke for the first time: “¿Voy a poder jugar fútbol otra vez?” (Am I going to be able to play soccer again?)

Isabel paused. “Ese es el objetivo de todo esto,” she said. “No te lo puedo prometer ahora mismo, pero si la quimio funciona bien y el cirujano puede conservar la rodilla, sí es posible. Y el camino más directo a eso es empezar la quimio esta semana.” (That is the goal of all of this. I cannot promise it to you right now, but if the chemotherapy works well and the surgeon can preserve the knee, yes it is possible. And the most direct path to that is starting chemotherapy this week.)

Miguel nodded. Rosa signed the consent forms.

At week 12, the repeat MRI showed a 4.2 cm residual lesion with cortical reconstitution and no soft-tissue extension. The surgeon performed a wide distal femur resection with endoprosthetic reconstruction. Pathological necrosis was 94 percent. Isabel ran into Miguel in the physical therapy department eight months later, walking with a cane but walking: “La enfermera que me explicó por qué primero la quimio.” (The nurse who explained why chemotherapy first.)

Key phrases for Ewing sarcoma neoadjuvant conversations

“El sarcoma de Ewing ya es una enfermedad del cuerpo entero en el momento del diagnóstico.” (Ewing sarcoma is already a whole-body disease at the time of diagnosis.)
“Las células ya salieron al torrente sanguíneo antes del diagnóstico, aunque las imágenes no las muestren.” (The cells have already entered the bloodstream before diagnosis, even though the images do not show them.)
“La quimioterapia trata el cuerpo entero. La cirugía solo trata el hueso.” (Chemotherapy treats the whole body. Surgery only treats the bone.)
“La respuesta del tumor a la quimio — cuánto porciento murió — es el dato más importante de todo el tratamiento.” (The tumor’s response to chemotherapy — what percentage died — is the most important data point in the entire treatment.)
“Empezamos la quimio esta semana para que el cirujano pueda conservar la pierna.” (We start chemotherapy this week so the surgeon can preserve the leg.)

Scenario 2: Carmen Delgado — 34, bilingual teacher from Miami, giant cell tumor of the distal radius

Carmen Delgado is thirty-four years old, a bilingual elementary school teacher from Miami who presented with eight months of worsening right wrist pain and swelling, initially attributed to carpal tunnel syndrome. A wrist radiograph showed a lytic epiphyseal lesion of the distal radius with cortical thinning and expansion but no cortical breakthrough. MRI confirmed a 4.1 cm lobulated intraosseous lesion with no associated soft-tissue mass and no vascular invasion. CT-guided core needle biopsy confirmed giant cell tumor of bone, Campanacci grade 2.

At her three-month denosumab follow-up appointment in the orthopedic oncology clinic, Carmen arrived with a written list of questions. Her mother had been sending her articles in Spanish — mostly from Costa Rican health websites — expressing concern that the tumor had not been removed. Her family in Costa Rica was worried. “My uncle who is a doctor there says he doesn’t understand why they treated the tumor instead of removing it,” she told nurse Carlos Méndez. “He says if you have a tumor in your bone, you remove the bone.”

Carlos sat across from Carmen and began where her uncle’s model diverged from the clinical reality.

“Su tío tiene razón en un principio general,” he said. “Si usted tuviera un tumor maligno en el radio distal, la resección sería el tratamiento correcto. Pero el tumor de células gigantes del hueso es un tipo diferente. Le voy a explicar exactamente por qué, porque creo que cuando entienda la biología, va a entender por qué hicimos lo que hicimos.” (Your uncle is correct as a general principle. If you had a malignant tumor in the distal radius, resection would be the correct treatment. But giant cell tumor of bone is a different type. I am going to explain exactly why, because I think when you understand the biology, you will understand why we did what we did.)

He explained the classification. The WHO grades giant cell tumor of bone as grade 2 to 3: locally aggressive, meaning it destroys surrounding bone and can recur, but biologically benign, meaning it does not send cells through the lymphatic system to lymph nodes and does not metastasize to distant organs in the conventional sense. The 1 to 3 percent of cases that do metastasize to the lung are called “benign pulmonary metastases” and behave differently from malignant lung metastases — they are typically slow-growing and often resectable. The primary threat of giant cell tumor of bone is local: recurrence in the original site if residual tumor cells are left after treatment.

“El riesgo del tumor de células gigantes no es que se disemine al pulmón o a los ganglios linfáticos como lo hace el cáncer,” he said. “El riesgo es que si quedan células después del tratamiento, el tumor puede crecer de nuevo aquí en el radio. Eso se detecta con imágenes de seguimiento — cada tres meses durante los primeros dos años — y si ocurre, se trata de nuevo. No es una catástrofe. Es un resultado que tenemos que vigilar y estamos vigilando.” (The risk of giant cell tumor is not that it spreads to the lung or lymph nodes the way cancer does. The risk is that if cells remain after treatment, the tumor can grow back here in the radius. That is detected on follow-up imaging — every three months for the first two years — and if it occurs, it is treated again. It is not a catastrophe. It is an outcome we need to watch for and we are watching for.)

Carmen interjected: “Pero si quitan todo el hueso, no puede crecer de nuevo, ¿verdad?” (But if they remove the entire bone, it cannot grow back, right?)

“Correcto,” Carlos said. “La resección completa del radio distal da cero recurrencia local. Eso es cierto. Pero necesito explicarle lo que significa quitar el radio distal.” (Correct. Complete resection of the distal radius gives zero local recurrence. That is true. But I need to explain what removing the distal radius means.)

He drew a quick sketch. The distal radius is the bone that forms the radiocarpal joint — the wrist joint on the thumb side. It articulates with the scaphoid and lunate carpal bones and with the distal ulna through the triangular fibrocartilage complex. Removing it entirely requires reconstruction. The two standard reconstructions at this site are: (1) a fibular strut graft, harvesting 8 to 10 cm of the patient’s own fibula from the same leg, and using it to replace the resected radius, allowing the fibula to articulate with the carpal bones and then undergo biological incorporation over two to three years; (2) wrist arthrodesis, fusing the wrist in a fixed functional position. Both produce significant permanent loss of function.

“El injerto del peroné da un rango de movimiento limitado, entre el 40 y el 60 porciento del movimiento normal de la muñeca, y una fuerza de agarre reducida, aproximadamente el 60 al 70 porciento del lado opuesto. La artrodesis — la fusión — elimina completamente la flexión y extensión de la muñeca. Usted quedaría con la muñeca fija en posición de extensión neutral o leve.” (The fibular graft gives a limited range of motion, between 40 and 60 percent of normal wrist movement, and a reduced grip strength, approximately 60 to 70 percent of the opposite side. The arthrodesis — the fusion — completely eliminates flexion and extension of the wrist. You would be left with the wrist fixed in neutral or slight extension position.)

Carmen stared at him. “Para siempre?” (Permanently?)

“Para siempre. Usted es maestra bilingüe. Escribe en la pizarra, escribe en hojas de trabajo, escribe informes, usa el teclado. Con una artrodesis de la muñeca derecha, esas actividades quedan permanentemente limitadas.” (Permanently. You are a bilingual teacher. You write on the board, you write on worksheets, you write reports, you use the keyboard. With a right wrist arthrodesis, those activities are permanently limited.)

He continued: the extended curettage — removing the tumor from inside the bone with curettes and a high-speed burr, treating the cavity walls with phenol or argon beam coagulation, and filling the cavity with bone cement — achieves local control in 75 to 85 percent of cases at the distal radius. The local recurrence rate of 15 to 25 percent sounds alarming, but it must be read against what the recurrence looks like: it appears on MRI as a new lytic focus at the treated site, detectable at the three-month imaging, and treatable with re-curettage in the majority of cases. It is not metastatic spread. It is not a change in prognosis. It is a treatable local event.

“El denosumab que está tomando cambia este cálculo,” he said. “El tumor de células gigantes destruye el hueso porque las células del tumor expresan RANK-L, una señal que activa los osteoclastos — las células que normalmente resorben hueso. El denosumab bloquea el RANK-L completamente. Sin esa señal, los osteoclastos no se activan, y el tumor deja de destruir hueso. Con el tiempo, el cuerpo deposita hueso nuevo en la cavidad. Ese proceso se llama osificación del tumor, y lo vemos claramente en sus imágenes del mes pasado — las paredes del hueso están más gruesas que en el diagnóstico.” (The denosumab you are taking changes this calculation. Giant cell tumor destroys bone because the tumor cells express RANK-L, a signal that activates osteoclasts — the cells that normally resorb bone. Denosumab completely blocks RANK-L. Without that signal, osteoclasts are not activated, and the tumor stops destroying bone. Over time, the body deposits new bone in the cavity. That process is called tumor ossification, and we can see it clearly in your imaging from last month — the bone walls are thicker than at diagnosis.)

“Después de seis meses de denosumab,” he continued, “la cirugía de raspado va a operar sobre un tumor que está parcialmente osificado, con paredes de hueso más gruesas y una cavidad más definida. Eso hace que el raspado sea más completo y reduce el riesgo de que queden células. Es por eso que la secuencia es denosumab primero, cirugía después. El objetivo es preservar la función de su muñeca derecha mientras controlamos el tumor. Eso es lo que estamos haciendo.” (After six months of denosumab, the curettage surgery will operate on a tumor that is partially ossified, with thicker bone walls and a more defined cavity. That makes the curettage more complete and reduces the risk of residual cells. That is why the sequence is denosumab first, surgery after. The goal is to preserve the function of your right wrist while controlling the tumor. That is what we are doing.)

Carmen was quiet for a moment. Then: “¿Y qué le digo a mi tío?” (And what do I tell my uncle?)

Carlos smiled. “Dígale que el cirujano eligió entre cero recurrencia y una muñeca que no funciona, o quince a veinticinco porciento de recurrencia tratable y una muñeca que funciona. Y eligió la muñeca.” (Tell him the surgeon chose between zero recurrence and a non-functional wrist, or 15 to 25 percent treatable recurrence and a functioning wrist. And he chose the wrist.)

At six months, the MRI showed significant cortical reconstitution with near-complete ossification of the central tumor. Extended curettage with argon beam and PMMA cementation was performed. At two-year follow-up, no recurrence. Grip strength 88 percent of the contralateral side. Carmen was still teaching. Her uncle sent a note through her asking for the citation for the denosumab data.

Key phrases for giant cell tumor of bone conversations

“Este tumor no se disemina al sistema linfático como el cáncer. El riesgo es que crezca de nuevo en el mismo lugar.” (This tumor does not spread through the lymphatic system like cancer. The risk is that it grows back in the same place.)
“Quitar el radio distal completamente curaría el tumor pero dejaría su muñeca permanentemente sin movimiento.” (Removing the distal radius completely would cure the tumor but would leave your wrist permanently without movement.)
“El denosumab hace que el tumor deje de destruir hueso y que el hueso se recupere. Eso hace que la cirugía de raspado sea más completa.” (Denosumab causes the tumor to stop destroying bone and the bone to recover. That makes the curettage surgery more complete.)
“El raspado controla el tumor en el 75 al 85 porciento de los casos con la función de la muñeca preservada.” (Curettage controls the tumor in 75 to 85 percent of cases with wrist function preserved.)
“Si el tumor creciera de nuevo, lo detectamos en las imágenes y se puede tratar de nuevo. No es una metástasis, es una recurrencia local.” (If the tumor were to grow back, we detect it on imaging and it can be treated again. It is not a metastasis, it is a local recurrence.)

Scenario 3: Diego Morales — 14, soccer player from East Los Angeles, osteosarcoma of the proximal tibia

Diego Morales is fourteen years old, a competitive soccer player from East Los Angeles who presented after three months of worsening right knee pain attributed to a sports injury. A knee radiograph taken at an urgent care visit showed a poorly defined mixed lytic and blastic lesion of the proximal tibia metaphysis with periosteal elevation and a soft-tissue mass. He was referred to the orthopedic oncology clinic within 48 hours. MRI confirmed a 7.8 cm lesion with cortical breakthrough and anterior soft-tissue mass extension involving but not encasing the anterior tibial vessels. CT of the chest showed two 4 mm pulmonary nodules of indeterminate significance. Bone scan showed uptake limited to the primary lesion. Open biopsy confirmed high-grade conventional osteosarcoma, osteoblastic subtype.

At the first oncology appointment, Diego’s parents — Marco and Elena Morales, construction contractor and homemaker from Oaxaca with permanent US residency — were visibly distressed. Marco had already called a cousin in Mexico City who knew of a cancer center at a major university there. “Queremos llevarlo a México,” he said immediately. “Allá tienen un centro especializado en cáncer de huesos. Queremos que lo vean allá antes de empezar cualquier cosa.” (We want to take him to Mexico. There they have a center specialized in bone cancer. We want them to see him there before starting anything.)

Elena added: “Es que si van a empezar un tratamiento tan fuerte, queremos estar seguros de que es el correcto. ¿No es razonable querer una segunda opinión?” (It is that if they are going to start such an aggressive treatment, we want to be sure it is the correct one. Is it not reasonable to want a second opinion?)

Nurse Ana García had worked in orthopedic oncology for seven years. She knew that this conversation required two things simultaneously: fully validating the parents’ request and explaining the specific medical reality that made the logistics of fulfilling it matter enormously.

“Una segunda opinión es completamente razonable y correcta,” she said. “Los apoyamos en eso. El diagnóstico es serio. El tratamiento es largo y difícil. Tienen todo el derecho de estar seguros antes de empezar. Y quiero explicarles cómo obtener esa segunda opinión sin que eso cambie las posibilidades de Diego a largo plazo, porque hay una manera de hacer ambas cosas a la vez.” (A second opinion is completely reasonable and correct. We support you in that. The diagnosis is serious. The treatment is long and difficult. You have every right to be sure before starting. And I want to explain how to obtain that second opinion without it changing Diego’s long-term chances, because there is a way to do both at the same time.)

She began with the biology. Osteosarcoma treated with the MAP protocol — high-dose methotrexate, doxorubicin, and cisplatin given in three neoadjuvant cycles over approximately ten weeks before surgery — has a five-year overall survival of 65 to 70 percent for localized disease. For metastatic osteosarcoma, the five-year survival drops to 20 to 30 percent. The two 4 mm pulmonary nodules on Diego’s CT were below the threshold for definitive characterization as metastases but would be watched closely.

The most important prognostic variable in osteosarcoma — the number that the entire oncology team would look at after surgery and that would determine the intensity of subsequent chemotherapy — is histological response. The surgeon removes the tumor after neoadjuvant chemotherapy. The pathologist analyzes what percentage of tumor cells are dead. Greater than 90 percent necrosis is a good histological response and predicts a five-year event-free survival of approximately 70 to 80 percent. Less than 90 percent necrosis is a poor histological response and is associated with a five-year event-free survival of approximately 40 to 50 percent, often triggering intensification of adjuvant chemotherapy or enrollment in clinical trials.

“Ese porcentaje — cuánto porciento del tumor murió con la quimio — depende de cómo estaba el tumor cuando empezó la quimioterapia,” Ana said. “El osteosarcoma en este momento está creciendo activamente. Tiene muchas células dividiéndose, y la quimioterapia actúa sobre las células que se están dividiendo. Cada semana que el tumor sigue creciendo sin tratamiento, desarrolla más circulación de sangre dentro del tumor. Esa nueva circulación crea áreas con poco oxígeno. Las células en áreas con poco oxígeno se están dividiendo más despacio y tienen mecanismos de resistencia a la quimioterapia. El tumor que empieza tratamiento hoy tiene más células sensibles a la quimio que el tumor que empieza tratamiento en seis semanas.” (That percentage — what percentage of the tumor was killed by chemotherapy — depends on how the tumor was when chemotherapy began. Osteosarcoma at this moment is actively growing. It has many cells dividing, and chemotherapy acts on dividing cells. Every week the tumor continues growing without treatment, it develops more blood circulation inside the tumor. That new circulation creates areas with low oxygen. Cells in low-oxygen areas are dividing more slowly and have mechanisms of chemotherapy resistance. The tumor that starts treatment today has more chemotherapy-sensitive cells than the tumor that starts treatment in six weeks.)

Marco frowned. “¿Pero seis semanas hace tanta diferencia?” (But does six weeks make that much difference?)

“La diferencia no es catastrófica. Pero es real. Y la mejor respuesta histológica que podemos lograr — el mayor porciento de células muertas — depende de empezar cuando el tumor es más sensible. Por eso el equipo quiere empezar esta semana.” (The difference is not catastrophic. But it is real. And the best histological response we can achieve — the highest percentage of dead cells — depends on starting when the tumor is most sensitive. That is why the team wants to start this week.)

She moved to the logistics. “Ahora les voy a explicar cómo funciona la segunda opinión,” she said. “Todo lo que el equipo de México va a necesitar está ya aquí. El MRI, el CT del tórax, el PET, el gammagrama óseo, los resultados de la biopsia — todo eso se puede exportar en formato digital y enviar por correo electrónico a cualquier hospital en México en 24 horas. Los bloques de parafina de la biopsia — el tejido físico — los enviamos por mensajería a cualquier departamento de patología en México en tres a cinco días hábiles. Con eso, el equipo en México puede revisar el caso completo y dar su opinión.” (Now I am going to explain how the second opinion works. Everything the team in Mexico will need is already here. The MRI, the CT of the chest, the PET, the bone scan, the biopsy results — all of that can be exported in digital format and sent by email to any hospital in Mexico within 24 hours. The paraffin blocks from the biopsy — the physical tissue — we send by courier to any pathology department in Mexico within three to five business days. With that, the team in Mexico can review the complete case and give their opinion.)

“Pueden tener una videollamada con el oncólogo en México mientras Diego esté aquí en tratamiento,” she continued. “No necesitan ir a México para la segunda opinión. Y si después de esa consulta deciden continuar el tratamiento allá, el protocolo que vamos a usar aquí es el MAP — metotrexato, doxorrubicina, cisplatino. Es el estándar internacional. Los centros de sarcoma en el INCAN, en el Hospital Juárez, en el Hospital Español en México City usan el mismo protocolo. Diego puede empezar aquí y continuar allá sin cambiar el tratamiento. Lo único que se pierde si esperamos es el tiempo.” (You can have a video call with the oncologist in Mexico while Diego is here in treatment. You do not need to go to Mexico for the second opinion. And if after that consultation you decide to continue treatment there, the protocol we are going to use here is MAP — methotrexate, doxorubicin, cisplatin. It is the international standard. The sarcoma centers at INCAN, at Hospital Juárez, at Hospital Español in Mexico City use the same protocol. Diego can start here and continue there without changing the treatment. The only thing that is lost if we wait is time.)

Elena began to cry quietly. “¿Por qué a él?” she said. (Why him?)

Ana paused. This question was not a clinical question. “No lo sé,” she said simply. “No hay una respuesta para eso. Lo que sí sé es que estamos aquí con ustedes y con Diego, y que vamos a hacer todo lo posible.” (I do not know. There is no answer to that. What I do know is that we are here with you and with Diego, and that we are going to do everything possible.)

The family agreed to start neoadjuvant chemotherapy that week. Ana helped them export the imaging files and shipped the biopsy blocks to a sarcoma pathologist at INCAN in Mexico City the next morning. The telemedicine consult with the INCAN oncologist occurred at week two of treatment; the INCAN team confirmed the MAP protocol and offered to continue treatment if the family relocated. They did not. At week 10, the repeat MRI showed a 4.1 cm residual lesion with cortical reconstitution. The surgeon performed a limb-sparing proximal tibia resection with endoprosthetic reconstruction. Pathological necrosis was 92 percent. The two pulmonary nodules were stable and re-characterized as benign calcified granulomas at 12-month CT. Diego was enrolled in post-operative adjuvant chemotherapy. At eighteen months he was attending school full-time and had been cleared by physical therapy to begin light cycling.

Key phrases for osteosarcoma treatment delay conversations

“Una segunda opinión es completamente razonable. Los apoyamos en eso.” (A second opinion is completely reasonable. We support you in that.)
“La segunda opinión no tiene que retrasar el inicio del tratamiento. Podemos hacer ambas cosas a la vez.” (The second opinion does not have to delay the start of treatment. We can do both at the same time.)
“Podemos enviar todas las imágenes y los bloques de biopsia a México en días, mientras Diego empieza la quimioterapia aquí.” (We can send all the images and biopsy blocks to Mexico within days, while Diego starts chemotherapy here.)
“El protocolo MAP es el estándar internacional. Los centros de sarcoma en México usan el mismo protocolo.” (The MAP protocol is the international standard. Sarcoma centers in Mexico use the same protocol.)
“Diego puede empezar aquí y continuar allá sin cambiar el tratamiento si deciden transferir el cuidado.” (Diego can start here and continue there without changing the treatment if you decide to transfer care.)
“Lo único que se pierde si esperamos es el tiempo.” (The only thing that is lost if we wait is time.)

Six practical Spanish phrases for orthopedic oncology clinic conversations

“La quimioterapia va primero porque el cáncer ya está en el cuerpo entero, aunque las imágenes solo muestren un lugar.” (Chemotherapy comes first because the cancer is already in the whole body, even though the images only show one place.) — For Ewing sarcoma and osteosarcoma neoadjuvant conversations.
“La respuesta del tumor a la quimio — cuánto porciento murió — es el dato más importante de todo el tratamiento.” (The tumor’s response to chemotherapy — what percentage died — is the most important data point in the entire treatment.) — For explaining why histological response matters.
“Quitar el tumor completamente curaría el tumor pero destruiría la función de la articulación permanentemente.” (Removing the tumor completely would cure the tumor but would permanently destroy joint function.) — For giant cell tumor curettage vs. resection conversations.
“El denosumab hace que el hueso se recupere antes de la cirugía, para que la cirugía sea más completa.” (Denosumab causes the bone to recover before surgery, so the surgery can be more complete.) — For explaining denosumab in giant cell tumor.
“Podemos enviar todas las imágenes y la biopsia a México en días, mientras empieza la quimioterapia aquí.” (We can send all the images and biopsy to Mexico within days, while chemotherapy starts here.) — For families considering treatment at an international center.
“Lo único que se pierde si esperamos es el tiempo.” (The only thing that is lost if we wait is time.) — For any conversation about treatment delay.

FAQ: Orthopedic oncology clinic Spanish conversations

How do I explain neoadjuvant chemotherapy before surgery to a family who believes surgery should come first?: Frame it around the systemic nature of the disease at diagnosis. Ewing sarcoma and osteosarcoma are whole-body diseases at the time of diagnosis. Surgery treats the primary tumor; chemotherapy treats the micrometastatic burden the imaging cannot show. The histological response — the percentage of tumor necrosis at surgery — is the strongest prognostic factor and only exists if chemotherapy is given first. In Spanish: “La cirugía quita el tumor del hueso. La quimioterapia trata las células que ya están en el resto del cuerpo. Necesitamos las dos. Empezamos con la quimioterapia porque trata el cuerpo entero y porque la respuesta del tumor a la quimio nos dice cuánto está funcionando el tratamiento.”
What is giant cell tumor of bone and why is curettage rather than resection the standard of care?: Giant cell tumor of bone is a WHO grade 2–3 locally aggressive but biologically benign tumor. It does not metastasize through lymphatics. Its risk is local recurrence. Wide resection eliminates local recurrence but destroys joint function at weight-bearing sites. Extended curettage with adjuvant and bone cement achieves local control in 75 to 85 percent of cases while preserving joint function. Denosumab (RANK-L inhibitor) causes tumor ossification and cortical reconstitution before surgery, improving curettage completeness. For the distal radius, wide resection requires fibular graft or wrist arthrodesis with permanent functional loss; curettage preserves the wrist.
Can a family with a child diagnosed with osteosarcoma get a second opinion abroad without delaying treatment?: Yes. All imaging (MRI, CT, PET) can be exported as DICOM files and sent electronically to any international center within 24 hours. Biopsy paraffin blocks can be shipped physically to any pathology department within three to five business days. A telemedicine consultation with the second-opinion team can be conducted during the first weeks of treatment. The MAP protocol (methotrexate, doxorubicin, cisplatin) is the international standard used at sarcoma centers throughout Mexico and Latin America. Treatment can begin here and continue at the international center without protocol discontinuity if the family decides to transfer care.
Why does the timing of starting neoadjuvant chemotherapy matter in osteosarcoma?: Osteosarcoma is a highly proliferative tumor at diagnosis. Neoadjuvant chemotherapy kills actively dividing cells. As the tumor grows without treatment, it develops new vascular ingrowth, creating hypoxic microenvironments where cells divide more slowly and upregulate drug efflux and hypoxia-inducible resistance pathways. Tumors with more hypoxic adaptation at the start of treatment achieve lower histological necrosis rates. Histological necrosis greater than 90 percent (good response) is associated with a five-year event-free survival of 70 to 80 percent versus 40 to 50 percent for poor response. Starting chemotherapy while the tumor is maximally sensitive preserves the best achievable histological response.
How do orthopedic oncology nurses support Spanish-speaking families who need extended-network consensus before agreeing to treatment?: Validate the family structure explicitly and offer to bring the extended network into the conversation directly: arrange a video call with the family member abroad and the oncology team so that second-hand accounts filtered through fear do not substitute for firsthand explanation. Provide a one-page written summary in Spanish of the diagnosis, treatment rationale, and international care logistics for the family to share. Frame a realistic timeline: four to five days is typically enough time to consult family, conduct a telemedicine consult with an international center, and make a decision — without incurring the treatment delay that changes histological response. Say explicitly: “Estamos aquí para ayudarles a obtener la información que necesitan para tomar la decisión correcta. No estamos pidiendo que confíen ciegamente. Estamos pidiendo que empecemos mientras usted verifica.” (We are here to help you obtain the information you need to make the correct decision. We are not asking you to trust blindly. We are asking you to start while you verify.)